Primary resistance to integrase inhibitors in Shenzhen.

Yue ZhuYuanmei HuangChenli ZhengJie TangGuang ZengWei XieHui WangLukun ZhangShaochu LiuYan ZhangWei TanJingguang TanLijuan JiangYun HeLiumei XuZhengrong YangJin Zhao

Published in: The Journal of antimicrobial chemotherapy (2023)

The prevalence of INSTI resistance in Shenzhen in 2020 was relatively high. Continued surveillance for resistance to INSTIs is recommended and treatment regimens should be adopted based on the pattern of resistance to INSTIs. Dolutegravir or bictegravir is first recommended when considering INSTIs as treatment regimens.

Keyphrases

public health
risk factors
combination therapy
antiretroviral therapy